ArticleJournal of medical ultrasonics (2001)2026
Contrast-enhanced ultrasound findings are associated with tumor viability and depth of response in selected patients with unresectable hepatocellular carcinoma treated with immunotherapy-based combination therapy.
Article in Journal of medical ultrasonics (2001), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of week-2 Contrast-Enhanced Ultrasound Perfusion Changes with Response to Lenvatinib Plus PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccurate evaluation of tumor viability during immunotherapy for unresectable hepatocellular carcinoma (HCC) remains challenging using contrast-enhanced computed tomography or magnetic resonance imaging (CECT/CEMRI), particularly after treatment-induced vascular changes. This exploratory study investigated whether contrast-enhanced ultrasound (CEUS) detects residual intratumoral perfusion differently from CECT/CEMRI and whether CEUS perfusion patterns are associated with depth of response (DpR) in selected patients receiving immunotherapy-based combination therapy.
methodsTwenty-five patients with unresectable HCC treated with atezolizumab plus bevacizumab, durvalumab plus tremelimumab, or nivolumab plus ipilimumab who underwent both CEUS and CECT/CEMRI within a 3-month interval were retrospectively analyzed. CEUS was performed at a median of 33 days after treatment initiation. Arterial-phase enhancement patterns were classified as hyper-, iso-, or hypoenhancement relative to surrounding liver parenchyma. Tumor response was evaluated using RECIST version 1.1 and modified RECIST. DpR was defined as the maximum percentage reduction in tumor size from baseline.
resultsCEUS demonstrated hyperenhancement in 14 lesions compared with six lesions on CECT/CEMRI. Enhancement patterns were discordant in 13 cases, with CEUS demonstrating hyperenhancement in 10 lesions classified as iso- or hypoenhancement on CECT/CEMRI (p = 0.049). Tumor size reduction did not differ significantly among enhancement categories on CECT/CEMRI (p = 0.325), whereas CEUS enhancement patterns were significantly associated with DpR (p = 0.008).
conclusionIn selected patients with unresectable HCC undergoing immunotherapy-based therapy, CEUS detected residual intratumoral perfusion more frequently than CECT/CEMRI and was significantly associated with DpR. CEUS may provide complementary information for exploratory assessment of tumor viability in this setting.
Indexed as
Identifiers
42377809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.